Background-In acute myocardial infarction patients who do not reperfuse their infarct arteries shortly after thrombolytic treatment have a high morbidity and mortality. Management of this high risk group remains problematic, especially in centres without access to interventional cardiology. Additional thrombolytic treatment may result in reperfusion and improved left ventricular function. Methods-Failure of reperfusion was assessed non-invasively as less than 25% reduction of ST elevation in the electrocardiographic lead with maximum ST shift on a pretreatment electrocardiogram. 37 patients with acute myocardial infarction who showed electrocardiographic evidence of failed reperfusion 30 minutes after 1.5 MU streptokinase over 60 minutes were randomly allocated to receive either alteplase (tissue type plasminogen activator (rt-PA) 100 mg over three hours) (19 patients) or placebo (18 patients). 43 patients with electrocardiographic evidence of reperfusion after streptokinase acted as controls. Outcome was assessed from the Selvester Q wave score of a predischarge electrocardiogram and a nuclear gated scan for left ventricular ejection fraction 4-6 weeks after discharge. Results-Among patients in whom ST segment elevation was not reduced after streptokinase, alteplase treatment resulted in a significantly smaller electrocardiographic infarct size (14% (8%) v 20% (90%), P = 0.03) and improved left ventricular ejection fraction (44 (10%) v 34% (16%), P = 0-04) compared with placebo. This benefit was confined to patients who failed fibrinogenolysis after streptokinase (fibrinogen > 1 gIl). In patients in whom ST segment elevation was reduced after streptokinase, infarct size and left ventricular ejection fraction were not significantly different from those in patients treated with additional alteplase. Conclusion-Patients without electrocardiographic evidence of reperfusion after streptokinase may benefit from further thrombolysis with alteplase. (Br Heart 7 1995;74:348-353) 
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(Br Heart it solely for comparison with potential infarct size (as assessed from the admission electrocardiogram), to assess non-invasively whether myocardial salvage had occurred. Interestingly, in our population Q wave score was significantly correlated with ejection fraction (r = 0-63, P < 0-001) in contrast to the data of Christian et al. '4 All electrocardiographs were scored by two experienced cardiologists, each of whom were unaware of treatment assignment or outcome. ST elevation was measured to the nearest 0 5 mm in all leads except aVR.
Left ventricular ejection fraction Left ventricular ejection fraction was assessed by nuclear gated blood pool imaging four to six weeks after hospital discharge. Global ejection fraction was estimated from the left anterior oblique projection with a standard computer software package. The left anterior oblique angulation was selected for each patient to achieve optimal separation of the right and left ventricles. (20) in the randomised group, P = 0-043). Mean time from the onset of symptoms to initiation of thrombolysis was 3-6 (1 9) hours (range 0-6-10 25) overall; in randomised patients the time from the onset of symptoms to initiation of rt-PA or placebo was 6-0 (2-1) hours (range 2-1-10-8). There were no systematic differences in time to treatment between the treatment groups. out of 43 (40%) control (streptokinase only) patients. The proportion of patients who did not show fibrinogenolysis was significantly higher among those later randomised-that is, those who presumably failed to reperfusethan among controls-that is those who presumably reperfused (65% compared with 40%, P = 0 01). Among randomised patients, seven of the 19 (37%) who received alteplase and six of the 18 (33%) who received placebo showed fibrinogenolysis after streptokinase (P = 0 9). Table 4 summarises the effect of fibrinogenolysis after streptokinase on infarct size and ejection fraction. In patients who showed neither reperfusion nor fibrinogenolysis after streptokinase, infarct size was significantly smaller and ejection fraction better preserved among those who received active alteplase than among those who received placebo; patients who received alteplase were not significantly different from those with presumed reperfusion after streptokinase alone. By contrast, in the group who did not show reperfusion but showed fibrinogenolysis after streptokinase there was no significant difference in either resultant infarct size or ejection fraction between alteplase and placebo groups. Likewise, among these patients, neither group was significantly different from patients with presumed reperfusion and fibrinogenolysis after streptokinase alone. In patients with presumed reperfusion after streptokinase alone outcome was similar regardless of fibrinogen concentration; fibrinogenolysis was not predictive of outcome.
EFFECTS ON INFARCT SIZE AND EJECTION FRACTION

MORTALITY AND COMPLICATIONS
Mortality at six weeks was 3-75%. Three patients died, one from each of the three treatment arms. There were five episodes of bleeding, only one of which, a gastrointestinal haemorrhage, required transfusion. This occurred in a patient randomly allocated placebo. Minor bleeds included two haemoptyses, one epistaxis, and one rectal bleed. There were no cerebral haemorrhages.
Discussion
In this prospective study we found that patients with acute myocardial infarction whose ST segment elevation did not reduce by 25% or more 90 minutes after initiation of streptokinase and who received additional lytic treatment with alteplase had improved left ventricular function and smaller Q wave scores than patients who received placebo. A prespecified subgroup analysis suggested that the improvement in outcome was confined to patients who also did not show fibrinogenolysis-that is, fibrinogen concentration was > 1 0 g/l after streptokinase. In the small group of patients without reduction in ST segment elevation 90 minutes after streptokinase and fibrinogen concentrations < 1 0 g/l, adjuvant alteplase conferred no extra benefit.
We chose a reduction in ST segment elevation of 25% or more as the non-invasive indicator of probable reperfusion. We previously found that this sign is highly sensitive (> 95%) but non-specific (43%) for coronary reperfusion when assessed angiographically 90 minutes after treatment with anisoylated streptokinase plasminogen activator complex. 7 Hogg et al reported a high sensitivity (93%) for a fall in ST segment elevation of 50%, but their post thrombolytic electrograms were recorded much later than in our study (at 302 (141) minutes).'6 When the criterion of Hogg et al was applied to a population with angiographically proved reperfusion at 90 minutes, sensitivity for reperfusion fell to only 68%.7
Frequent (every 5-10 minutes) measurement of ST segment height is a more sensitive indicator of reperfusion than sampling at two fixed points. Shah et al showed that comparison of a single pretreatment electrocardiogram with one taken at 90 minutes failed to detect impending reperfusion in more than 10% of patients.'7 If we had sampled ST segments more frequently, fewer patients may have received adjuvant thrombolysis. However, we wanted to identify failed reperfusion and to maximise the potential impact of alteplase in the patients who needed it-and this argued for treatment to be given as early as possible. Inevitably an arbitrary time limit must be applied in this situation and we chose 90 minutes after the initiation of streptokinase. A secondary consideration in the use of electrocardiographic assessment at fixed time points was a desire to test the efficacy of a management strategy which could be widely applied. Continuous ST segment monitoring requires more nursing time than is usually available in a busy coronary care unit. Relief of chest pain was not used in the current study because, although it is a sensitive sign of timing of reperfusion when followed sequentially,'7 its assessment at a fixed time point is difficult, especially if it is not concordant with the electrocardiographic results.
Adjuvant thrombolysis was administered when the patency of the infarcted artery would be expected to be 50-60% (thrombolysis in myocardial infarction (TIMI) grade II or III).' Patencies after streptokinase treatment improve to about 75% at three hours,' so if probable reperfusion status had been assessed at this stage the proportion of patients requiring additional lytic treatment would have been reduced. In the event, although the anticipated persistent occlusion rate was 40-50% at the time of assessment, only 33% of our patients met the electrocardiographic criteria for persistent occlusion. A fall in ST segment elevation of 25% or more is of limited value in predicting coronary patency-that is, the specificity is low-but, after single agent thrombolysis, patients who have such a fall but no angiographic evidence of reperfusion have well preserved left ventricular function.7 The converse electrocardiographic sign-persistent ST segment elevation after thrombolysis-is highly predictive of persistent coronary occlusion and impaired left ventricular function.7 In our previous study ejection fraction was as low as 28% in this group, compared with 47% in patients with reduced ST segment elevation of 25% or more.
The thrombolytic action of streptokinase is associated with a systemic lytic state; failure to achieve fibrinogenolysis 90 minutes after initiation of lytic treatment is associated with persistent coronary occlusion.'0 We found that when fibrinogen concentrations were measured at 60 minutes patients with presumed reperfusion-that is, those with reduced ST segment elevation-had an overall good outcome regardless of whether they showed fibrinogenolysis. Among the 40% of these who did not show fibrinogenolysis the favourable outcome may possibly be attributed to late fibrinogenolysis with subsequent clot lysis or to the presence of a preformed collateral circulation. In patients with presumed failed reperfusion-that is, persistent ST segment elevation-alteplase improved outcome only in the 65% with failed fibrinogenolysis-that is, fibrinogen concentration > 1 gIl. In those with fibrinogenolysis, outcome was good and not improved by rt-PA. A possible explanation of this is that, although streptokinase did not cause reperfusion it reduced plasma viscosity and so improved peri-infarct microcirculation sufficiently to limit infarct size. '8 19 The streptokinase induced reduction in plasma viscosity closely parallels fibrinogen concentrations and so will not occur in patients who do not show defibrination. Alternatively, these patients may have been destined to show reperfusion late with streptokinase alone, alteplase thus being of no further benefit.
Combination thrombolysis using streptokinase and rt-PA results in a superior patency rate (TIMI grade II or III) at 90 minutes when compared with either rt-PA or streptokinase given as monotherapy in conventional regimens.56 In the GUSTO (global utilisation of streptokinase and alteplase for occluded coronary arteries) trial this improvement in patency did not translate to an improvement in either left ventricular function or mortality6-only accelerated alteplase was superior to the other regimens in this respect.' Also in the GUSTO trial-and presumably also in the general population of patients with infarction-flow of TIMI grade III at 90 minutes achieved by whatever regimen was the best predictor of outcome. Left ventricular function was identical in the groups with flow of TIMI grades 0, I, and II at 90 minutes. Our data are not strictly comparable with either those of the GUSTO6 or KAMIT (Kentucky acute myocardial infarction)5 trials. We studied patients treated initially with streptokinase, presumably with flow of TIMI grade 0 or I flow at 90 minutes and found an improved outcome after additional, delayed rt-PA treatment. A high risk population was selected for intervention and, by the surrogate end point of left ventricular function, an improvement was observed. This improvement was similar in magnitude to that observed in the ISAM (intravenous streptokinase in acute myocardial infarction) trial of streptokinase and placebo,20 but it was much larger than that observed early after infarction in the TAMI (thrombolysis and angioplasty in myocardial infarction) and TIMI (thrombolysis in acute myocardial infarction) trials.2' 22 The value of left ventricular function as a surrogate end point in trials of lytic treatment has been questioned.2324 In the general population of patients with infarction ejection fraction is about 50% in both thrombolytic and placebo groups. 24 We observed a greater ejection fraction in the treatment group probably because the study population was confined to high risk patients with persistently occluded arteries. These patients had most left ventricle to gain, or lose. A larger trial would be needed to determine whether the improvement in left ventricular function we observed would translate into a mortality benefit.
Rescue angioplasty has been advocated for patients with persistent coronary occlusion or early recurrent ischaemia after thrombolysis.25 Repeat thrombolysis is beneficial in patients with early recurrent ischaemia after myocardial infarction.4 Our data suggest that additional lytic treatment may also be beneficial in patients with evidence of persistent coronary occlusion after thrombolysis. Most cardiac centres do not have access to immediate angioplasty; our data suggest that additional thrombolysis may be substituted with benefit to the patient.
Combination thrombolysis results in a significant excess of haemorrhagic strokes over single agent thrombolysis in all regimens so far tested. In GUSTO the haemorrhagic stroke rate for combination treatment was 0.94%,6 which is almost double the rate for streptokinase alone, 0 49-0 54%. We did not set up our study to test formally the safety profile of combination thrombolytic treatment in persistent coronary occlusion, but the absence of treatment related complications suggests that serious haemorrhage rates greatly in excess of those seen in GUSTO are unlikely.
In conclusion, among patients with acute myocardial infarction in whom streptokinase does not reduce ST segment elevation by 25% or more after 90 minutes, further thrombolysis with rt-PA resulted in significantly better left ventricular function and a smaller resultant electrocardiographic infarct size when compared with placebo. This improvement in infarct size and left ventricular function was confined to patients who did not show fibrinogenolysis (fibrinogen concentration > 1 g/l) after streptokinase. These findings need to be confirmed in a larger, preferably multicentre, trial. Our data suggest, however, that in acute myocardial infarction treatment with an additional thrombolytic agent should be considered if ST segment elevation fails to resolve and if plasma fibrinogen concentration remains above 1-0 g/l.
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